Pharmacokinetic interaction between efavirenz and ketoconazole in rats

References

• Aarnoutse RE, Grintjes KJ, Telgt DS, Stek M Jr, Hugen PW, Reiss P, Koopmans PP, Hekster YA, Burger DM. 2002. The influence of efavirenz on the pharmacokinetics of a twice-daily combination of indinavir and low-dose ritonavir in healthy volunteers. Clin Pharmacol Ther 71(1):57–67.
   Google Scholar
• Adkins JC, Noble S. 1998. Efavirenz. Drugs 56(6):1055–1064.
   Google Scholar
• Ahonen J, Olkkola KT, Neuvonen PJ. 1997. Effect of route of administration of fluconazole on the interaction between fluconazole and midazolam. Eur J Clin Pharmacol 51(5):415–419.
   PubMed Web of Science ®Google Scholar
• Allqvist A, Miura J, Bertilsson L, Mirghani RA. 2007. Inhibition of CYP3A4 and CYP3A5 catalyzed metabolism of alprazolam and quinine by ketoconazoleas racemate and four different enantiomers. Eur J Clin Pharmacol 63(2):173–179.
   Google Scholar
• Balani SK, Kauffman LR, deLuna FA, Lin JH. 1999. Nonlinear pharmacokinetics of efavirenz (DMP-266), a potent HIV-1 reverse transcriptase inhibitor, in rats and monkeys. Drug Metab Dispos 27(1):41–45.
   Google Scholar
• Bodemar G, Norlander B, Fransson L, Walan A. 1979. The absorption of cimetidine before and during maintenance treatment with cimetidine and the influence of a meal on the absorption of cimetidine — studies in patients with peptic ulcer disease. Br J Clin Pharmacol 7(1):23–31.
   Google Scholar
• Brian WR, Sari MA, Iwasaki M, Shimada T, Kaminsky LS, Guengerich FP. 1990. Catalytic activities of human liver cytochrome P-450IIIA4 expressed in Saccharomyces cerevisiae. Biochemistry 29(51):1280–1292.
   Google Scholar
• Clarke SM, Mulcahy FM, Tjia J, Reynolds HE, Gibbons SE, Barry MG, Back DJ. 2001. The pharmacokinetics of methadone in HIV-positive patients receiving the non-nucleoside reverse transcriptase inhibitor efavirenz. Br J Clin Pharmacol 51:213–217.
   PubMed Web of Science ®Google Scholar
• Clements JA, Heading RC, Nimmo WS, Prescott LF. 1978. Kinetics of acetaminophen absorption and gastric emptying in man. Clin Pharmacol Ther 24(4):420–431.
   Google Scholar
• Department of Health and Human Services. 2006. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 10 October 2006 (available at: http://www.aidsinfo.nih.gov) (accessed on 20 December 2006).
   Google Scholar
• Falloon J, Piscitelli S, Vogel S, Sadler B, Mitsuya H, Kavlick MF, Yoshimura K, Rogers M, LaFon S, Manion DJ, Lane HC, Masur H. 2000. Combination therapy with amprenavir, abacavir, and efavirenz in human immunodeficiency virus (HIV)-infected patients failing a protease-inhibitor regimen: pharmacokinetic drug interactions and antiviral activity. Clin Infect Dis 30(2):313–318.
   Google Scholar
• Guengerich FP, Brian WR, Iwasaki M, Sari MA, Bäärnhielm C, Berntsson P. 1991. Oxidation of dihydropyridine calcium channel blockers and analogues by human liver cytochrome P450IIIA4. J Med Chem 34(6):1838–1844.
   Google Scholar
• Hariparsad N, Nallani SC, Sane RS, Buckley DJ, Buckley AR, Desai PB. 2004. Induction of CYP3A4 by efavirenz in primary human hepatocytes: comparison with rifampin and phenobarbital. J Clin Pharmacol 44(11):1273–1281.
   Google Scholar
• Heel RC, Brogden RN, Carmine A, Morley PA, Speight TM, Avery GS. 1982. Ketoconazole: a review of its therapeutic efficacy in superficial and systemic fungal infections. Drugs 23(1–2):1–36.
   Google Scholar
• Liu P, Foster G, LaBadie RR, Gutierrez MJ, Sharma A. 2008. Pharmacokinetic interaction between voriconazole and efavirenz at steady state in healthy male subjects. J Clin Pharmacol 48(1):73–84.
   PubMed Web of Science ®Google Scholar
• Mouly S, Lown KS, Kornhauser D, Joseph JL, Fiske WD, Benedek IH, Watkins PB. 2002. Hepatic but not intestinal CYP3A4 displays dose-dependent induction by efavirenz in humans. Clin Pharmacol Ther 72(1):1–9.
   Google Scholar
• Oberle RL, Amidon GL. 1987. The influence of variable gastric emptying and intestinal transit rates on the plasma levels of cimetidine. An explanation for the double peak phenomenon. J Pharm Biopharm 15(5): 529–544.
   Google Scholar
• Penzak SR, Gubbins PO, Gurley BJ, Wang PL, Saccente M. 1999. Grapefruit juice decreases the systemic availability of itraconazole capsules in healthy volunteers. Ther Drug Monit 21(3):304–309.
   PubMed Web of Science ®Google Scholar
• Sriwiriyajan S, Mahatthanatrakul W, Ridtitid W, Jaruratanasirikul S. 2007. Effect of efavirenz on the pharmacokinetics of ketoconazole in HIV-infected patients. Eur J Clin Pharmacol 63(5):479–483.
   Google Scholar
• Stresser DM, Broudy MI, Ho T, Cargill CE, Blanchard AP, Sharma R, Dandeneau AA, Goodwin JJ, Turner SD, Erve JC, Patten CJ, Dehal SS, Crespi CL. 2004. Highly selective inhibition of human CYP3A in vitro by azamulin and evidence that inhibition is irreversible. Drug Metab Disposit 32(1):105–112.
   Google Scholar
• Torres-Molina F, Peris JE, Garcia-Carbonell MC, Aristorena JC, Granero L, Chesa-Jimenez J. 1996. Use of rats chronically cannulated in the jugular vein and the duodenum in pharmacokinetic studies. Effect of ether anesthesia on absorption of amoxicillin. Arzneimittelforschung 46(7):716–719.
   Google Scholar
• Von Moltke LL, Greenblatt DJ, Granda BW, Giancarlo GM, Duan SX, Daily JP, Harmatz JS, Shader RI. 2001. Inhibition of human cytochrome P450 isoforms by nonnucleoside reverse transcriptase inhibitors. J Clin Pharmacol 41(1):85–91.
   Google Scholar
• Zimmerman JJ, Harper D, Getsy J, Jusko WJ. 2003. Pharmacokinetic interactions between sirolimus and microemulsion cyclosporine when orally administered jointly and 4 hours apart in healthy volunteers. J Clin Pharmacol 43(10):1168–1176.
   Google Scholar